Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- January15 2005
- Volume 12
- Issue 1
Addicted?
Advertisement
20 million—Number of barrels of oil consumed each day in the United States.
(Time, 2004)
7.5 million—Number of barrels of oil produced each day in the United States.
Articles in this issue
about 18 years ago
Change & Growth: Keys to a Satisfying Lifeabout 18 years ago
The Nanny Tax Returns—Be Readyabout 18 years ago
Acquaint Yourself with the New Year's Stock Possibilitiesabout 18 years ago
Mix and Match Your Portfolio Selectionsabout 18 years ago
Set Your Investment Strategy in Motionabout 18 years ago
Analyze the Buy-and-Hold Market Strategyabout 18 years ago
Foresee the Economy Under the Bush Administrationabout 18 years ago
Brokerages Pass the Responsibility Buckabout 18 years ago
Keep It Simple for a Smart Investment Strategyabout 18 years ago
Personalize Your Portfolio AccessoriesAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5